Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS) - A Randomized, Double-blind, Placebo-controlled Multicenter Study

NCT03287609 is registered in ClinicalTrials.gov with Insel Gruppe AG, University Hospital Bern as lead sponsor.

NCT NCT03287609
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03287609 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS) - A Randomized, Double-blind, Placebo-controlled Multicenter Study
Lead sponsor
Insel Gruppe AG, University Hospital Bern
Phase
Phase 3
Overall status
Completed
Start date
January 23, 2018
Completion date
August 7, 2019
Enrollment
308 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndrome